4 Result(s)

Article

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expressio...

Niki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, Sara Pilotto… in Scientific Reports (2015)

Article

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Non-small-cell lung cancer patients with activating epidermal growth factor receptor (EGFR) mutations typically benefit from EGFR tyrosine kinase inhibitor treatment. However, virtually all patients succumb t...

Kirstine Jacobsen, Jordi Bertran-Alamillo, Miguel Angel Molina… in Nature Communications (2017)

Article

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

Non-small cell lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs). Here, we show that resistant cells without the p.T790M or othe...

Jordi Bertran-Alamillo, Valérie Cattan, Marie Schoumacher… in Nature Communications (2019)

Article

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Niki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, Sara Pilotto… in Scientific Reports (2023)